Preliminary study results presented at the 2026 Military Health System Research Symposium (MHSRS) show reductions in evacuation and surgical treatment times in combat medical settings. MEDIA, Pa., Sept. 29, 2026 /PRNewswire-PRWeb/ -- InfraScan, Inc., a medical device company specializing in portable brain injury assessment technology, announced the completion of the…
Read More
TLB-33 adds a complementary mechanism and further expands Tolerance Bio’s clinical-stage pipeline targeting thymic biology Company planning Phase 2 clinical development beginning in 2027 as it builds a pipeline of complementary modalities to improve thymic function for better healthspan PHILADELPHIA, P.A. – September 28, 2026 - Tolerance Bio, Inc. (“Tolerance Bio” or…
Read More
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The American Medical Association (AMA) and Atalan today announced a new research collaboration focused on advancing understanding of the factors that influence physician retention across U.S. health systems. The two organizations have agreed to combine resources and launch the PROGRESS Study (Physician Retention,…
Read More
HOUSTON, Sept. 9, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announces the appointment of Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors. Dr. Reza Mazhari has more than 25 years of life science operating experience in drug discovery, early-stage clinical development and…
Read More
Bristol Myers Squibb and seasoned biotechnology veteran Donald Hayden, M.B.A., appointed as Chairman of the Latus Board of Directors Former Chief Financial Officer of Avidity Biosciences Michael MacLean appointed as independent director and Chair of the Audit Committee Appointments come as Latus advances its lead programs into clinical trials, including…
Read More
Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution PHILADELPHIA--(BUSINESS WIRE)--Tolerance Bio, Inc. (“Tolerance Bio”…
Read More
Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics· ARPA-H PROSPR Program
Melior Discovery will conduct preclinical in vivo pharmacology studies supporting Linnaeus' ARPA-H PROSPR-funded development of LNS880l for healthspan preservation EXTON, Pa., July 21, 2026 /PRNewswire-PRWeb/ -- Melior Discovery, Inc. (Melior), a dedicated in vivo pharmacology contract research organization (CRO) with deep expertise in phenotypic screening and preclinical model development, today…
Read More
The Coalition and American Hospital Association, AdventHealth, Atalan, and Providence’s Well Being Trust collaborate on practical framework for healthcare initiative evaluation ALTAMONTE SPRINGS, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- The Coalition for Physician & APP Well-Being, a non-profit entity comprised of national healthcare organizations dedicated to fostering the well-being…
Read More
PHILADELPHIA, June 25, 2026 (GLOBE NEWSWIRE) -- Nurse burnout remains a significant challenge in the healthcare industry, with growing interest in tools that can help identify retention risk earlier. Atalan for Nursing is intended to address this need. Atalan, the leading Clinician Retention Intelligence (CRI) platform, today announced the launch…
Read More
BCI’s second investment to advance therapeutic treatments for celiac disease will support preclinical development of novel approach to immune tolerance AMBLER, PA, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- Beyond Celiac Investments (BCI), the venture philanthropy program of Beyond Celiac, today announced an investment in Tolerance Bio Inc., to support…
Read More